Compliance
Arion Bios, Legal Framework for Supplying The peptide for Laboratory Research in the UK
Arion Bios accepts enquiries concerning the peptide for documented laboratory projects. This policy concerns the defined the peptide molecule associated with Eli Lilly’s development programme, as distinct from structurally modified analogues.
Chemical identity and manufacturing origin are separate matters. The peptide manufactured by another producer can have the same chemical structure. Establishing that identity requires appropriate analytical evidence; establishing the right to supply requires a separate legal assessment.
References to Eli Lilly identify the molecule’s development context.
The legal basis must cover Arion Bios’s own activities
The relevant framework is the Patents Act 1977. Where an applicable patent remains in force, section 60(1) addresses manufacture, offering, sale, import and possession of the patented product.
Arion Bios’s proposed supply policy requires a documented basis covering the relevant supplier activities before an offer or transaction proceeds. Potential grounds include:
Exhaustion concerns the particular goods placed on the market with consent.
Research-related exceptions: assessment of the actual supply
Section 60(5)(b) concerns experimental acts relating to the subject matter of the invention. A commercial research objective can coexist with a qualifying experimental purpose.
Sections 60(6D)-(6E) extend this framework to activities undertaken in or for a qualifying medicinal product assessment. Relevant purposes include generating information for marketing authorisation, meeting associated regulatory requirements and certain healthcare assessments.
For Arion Bios, the decisive issue is whether the specific acts involved in offering, preparing, importing or supplying material fall within the relevant exception. Section 60(6) also preserves an important distinction concerning indirect infringement.
Accordingly, a request for material for a defined regulatory study requires an assessment of the supplier’s role, the purpose of the activities and their connection to that study. General catalogue sales labelled “research use” require their own lawful basis.
Who may submit an enquiry
We welcome documented enquiries from:
These categories describe potential applicants. Eligibility for a particular supply depends on the legal basis available to Arion Bios, the product and the proposed activities.
Educational status alone creates no general exemption for a commercial sale of patented the peptide. A school or student may receive material through an appropriately authorised supply route; their status alone cannot establish that route.
Information required before a supply is accepted
The applicant must provide:
Arion Bios reviews the information before accepting the proposed supply. Additional project documents or confirmations may be required.
A statement such as “for research”, a university email address or acceptance of personal responsibility is insufficient by itself to establish the supplier’s legal position.
Laboratory material — not for administration to humans
FOR LABORATORY RESEARCH ONLY. NOT FOR HUMAN USE.
Material supplied under this policy is restricted to the laboratory activities approved for the transaction.
Prohibited uses include ingestion, injection, self-experimentation, treatment, weight management and preparation of products for administration to people. Human clinical administration falls outside this supply policy.
Under regulation 2 of the Human Medicines Regulations 2012, product classification depends on relevant characteristics, presentation and intended use. The MHRA considers the overall circumstances, including websites, advertising and customer communications. A research label alone cannot determine classification.
Documentation supporting the supplier’s position
Our proposed controls require a transaction record identifying the legal basis for supply, approved purpose, recipient, quantity and batch. Contractual restrictions must correspond to the actual transaction and the evidence obtained during review.
Customer declarations provide evidence of the agreed purpose. They neither replace the supplier’s assessment.
Arion Bios assesses the peptide enquiries against a documented supply route. Acceptance follows verification of both the proposed laboratory use and the company’s entitlement to carry out the transaction.
Arion Bios — Terms of Supply for Research Peptide Analogues in the UK
Arion Bios develops proprietary peptide reagents for laboratory research. We welcome enquiries from research teams, businesses, educational institutions and individuals conducting documented laboratory projects.
These terms concern Arion Bios’s proprietary the peptide analogue, identified by its chemical structure and product specification. An analogue is a distinct, structurally related molecule. Its characteristics and intended laboratory applications are described in the documentation for that specific product.
Our basis for supply: a lawful product, a defined purpose and a verified transaction
UK law provides a framework for the commercial supply of chemical substances, including reagents used in research and education. Three areas of regulation are particularly relevant to our activities.
1. Patent law — the scope of protection for a particular invention
Section 60 of the Patents Act 1977 identifies activities covered by patent protection, including offering for sale, selling and importing. Section 125 determines the scope of protection by reference to the patent claims, interpreted using the description and drawings.
For a proprietary analogue, freedom to supply depends on the product and relevant activities falling outside enforceable patent rights, or on the supplier holding appropriate authorisation. The assessment also considers protection for equivalent solutions and patents covering manufacturing processes.
Under this model, sales may generate profit, and customers may conduct research aimed at developing commercial technology. The supplier’s freedom to operate depends on the legal position of the product and transaction. A customer’s student status or academic affiliation is a separate consideration.
Describing a substance as an “analogue”, or developing a proprietary synthesis method, must be supported by an assessment of existing patent rights. Before introducing a product into the Arion Bios catalogue, our policy requires a documented legal basis for offering and supplying it.
2. Laboratory use — product classification
Regulation 2 of the Human Medicines Regulations 2012 defines a medicinal product. Classification considers the substance’s properties, intended purpose and presentation. The Medicines and Healthcare products Regulatory Agency (MHRA) also considers websites, advertising, packaging and communications with customers.
Arion Bios designates the reagent covered by these terms for chemical analysis, laboratory research and appropriately designed educational laboratory activities. Product documentation and commercial communications must reflect those applications.
“Research Use Only” describes the intended purpose. Legal classification depends on the product and the actual circumstances of its presentation and supply, rather than that label alone.
3. Chemical supply requirements
Supplies to England, Scotland and Wales are subject to applicable UK REACH and GB CLP requirements. These address matters including registration, classification, labelling, packaging and the communication of safety information, according to the substance, quantity and role of each party in the supply chain.
A research purpose does not, by itself, exempt a chemical placed on the market from these requirements. For supplies from Switzerland, the importer and the allocation of applicable responsibilities must also be established. Supplies to Northern Ireland require a separate assessment under the REACH and CLP arrangements applicable there.
Who may apply to purchase
We accept applications from:
Affiliation with a large institution is one way to substantiate a project. Applications are assessed individually.
These categories identify potential customers. Acceptance relates to the particular product, project and proposed supply.
Examples of projects considered
A student may apply to study peptide stability in a university laboratory. A teacher may propose an instrumental analysis exercise in an appropriately equipped teaching laboratory. A startup may be developing a method for measuring a substance. A contract laboratory may be investigating purity or degradation products.
In each case, we assess whether the reagent, quantity and proposed working conditions are appropriate for the stated activity. Use in a school requires particular consideration of the substance’s hazards and its suitability for the educational purpose.
How order verification works
When submitting an order request, the customer provides:
Arion Bios reviews this information before accepting the order for fulfilment. Depending on the project, we may request confirmation of laboratory access, a supervisor’s contact details, a description of the proposed method or documents required for the particular application.
A general statement such as “for research” requires further detail. Conflicting information, unsuitable working conditions or indications of intended human use are grounds for declining an order.
FOR LABORATORY RESEARCH ONLY — NOT FOR HUMAN USE
The reagent covered by this offer is supplied exclusively for laboratory work.
Prohibited uses include ingestion, injection, self-experimentation, administration to another person, weight management, treatment and the preparation of products intended for administration to humans.
Purchasing through a university, holding a medical qualification or signing a statement accepting personal responsibility does not override this restriction.
Clinical trials and supplies of materials intended for administration to humans fall outside the scope of this offer.
How Arion Bios safeguards its position as a supplier
Our supply model requires documented assessment of the product’s legal status, appropriate classification and presentation, compliance with applicable chemical supply requirements and genuine verification of proposed transactions.
Our policy requires records of the information supplied by the purchaser, the outcome of the assessment and the identity of the batch supplied. Contractual terms define permitted uses and customer obligations.
Customer declarations form part of the transaction record. They support verification and document the agreed purpose; the supplier’s own statutory responsibilities remain with the supplier.
Arion Bios welcomes academic, educational and commercial laboratory projects. Acceptance depends on the product’s legal status, the purpose of the supply and verified working conditions.
Laboratory Use and Liability
All products covered by this policy, including the peptide and Arion Bios peptide analogues, are supplied exclusively as laboratory research reagents. They are neither offered nor supplied as medicines, medicinal preparations, dietary supplements or products for human administration.
FOR LABORATORY RESEARCH ONLY. NOT FOR HUMAN USE.
Product descriptions, specifications and technical information relate solely to laboratory applications. They provide no medical advice, treatment recommendations or instructions for human dosing.
Customers must use, handle, store and dispose of each reagent in accordance with its documentation, the agreed laboratory purpose and applicable law.
To the extent permitted by applicable law, Arion Bios excludes liability for loss or damage to the extent caused by unauthorised use, human administration, improper handling or storage, or onward supply contrary to the agreed terms.
Nothing in this statement excludes or limits liability for death or personal injury caused by negligence, fraud or fraudulent misrepresentation, or any liability that applicable law prohibits excluding or limiting. Statutory product classification and the supplier’s legal obligations remain governed by applicable law.